BOSTON – Nonosense technology developer Nanowear was the $10,000 grand prize winner in the 2017 Philips Wearables Challenge at Harvard Medical School last month.
Nanowear is a connected-self technology platform for diagnostics and chronic disease management. The company recently received clearance from the U.S. Food & Drug Administration for its first product, SimplECG, a remote cardiac monitoring undergarment that collects continuous multi-channel ECG, heart rate and respiratory rate data, and transfers it to a web-based portal for review by a physician via a mobile application.
“This marks the company’s first FDA clearance, and reflects Nanowear’s strategy of differentiating itself in an otherwise crowded market for wearables, with an eye toward the future of the ‘connected self,’” said Dr. John Zimmerman, chief medical officer of Nanowear, in a statement. “SimplECG will provide an easier and more patient-friendly means of capturing and transmitting diagnostic data via everyday garments to monitor heart behavior and prevent cardiac-related events.”
Nanosense plans to develop an array of applications for its nanosensor technology, said Venk Varadan, co-founder and CEO of Nanowear.
“This is a big milestone for our young company,” he said in a statement. “The market of applications for health care alone is a multibillion-dollar opportunity, but as we look beyond to consumer, industrial, clinical research, military and public sector applications, the addressable market expands exponentially.”
Nanowear will now focus its efforts on product commercialization, strategic partnerships and continued development of complementary products and applications for chronic disease states, Varadan said.
Launched in summer of 2017, the Philips Wearables Challenge called for novel solutions to predict early signs of patient deterioration and prevent hospital readmission. Forty teams from across the country submitted their technologies and systems and six finalist teams were selected for voting.